Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 10 February 2016, 10:00 – 14:30

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Chair Professor Andrew Stevens Present for all notes
2. Prof Kathryn Abel Present for all notes
3. Dr Ian Bernstein Present for all notes
4. David Chandler Present for notes 01 to 07
5. Gail Coster Present for all notes
6. Professor Peter Crome Present for notes 01 to 07
7. Professor Rachel Elliott Present for all notes
8. Dr Nigel Langford Present for all notes
9. Dr Paul Miller Present for all notes
10. Professor Andrea Manca Present for all notes
11. Dr Patrick McKiernan Present for notes 01 to 07
12. Dr Anna O'Neill Present for all notes
13. Professor Andrew Renehan Present for all notes
14. Dr Claire Rothery Present for all notes
15. Dr Peter Selby Present for all notes
16. Prof Matt Stevenson Present for all notes
17. Dr Paul Tappenden Present for all notes
18. Professor Robert Walton Present for all notes
19. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Health and Care Excellence Present for all notes

Joanne Ekeledo Administrator, National Present for all notes
Institute for Health and Care Excellence

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anwar Jilani</td>
<td>Technical Analyst, National Institute for</td>
<td>04 to 07</td>
</tr>
<tr>
<td></td>
<td>Health and Care Excellence</td>
<td></td>
</tr>
<tr>
<td>Nicola Hay</td>
<td>Technical Adviser, National Institute for</td>
<td>04 to 07</td>
</tr>
<tr>
<td></td>
<td>Health and Clinical Excellence</td>
<td></td>
</tr>
<tr>
<td>Ian Watson</td>
<td>Technical Analyst, National Institute for</td>
<td>08 to 11</td>
</tr>
<tr>
<td></td>
<td>Health and Care Excellence</td>
<td></td>
</tr>
<tr>
<td>Joanne Holden</td>
<td>Technical Adviser, National Institute for</td>
<td>08 to 11</td>
</tr>
<tr>
<td></td>
<td>Health and Clinical Excellence</td>
<td></td>
</tr>
</tbody>
</table>

Non-public observers:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Edwards</td>
<td>ERG representative</td>
<td>04 to 06</td>
</tr>
<tr>
<td>Andrea Berardi</td>
<td>ERG representative</td>
<td>04 to 06</td>
</tr>
<tr>
<td>Adrian Bagust</td>
<td>ERG representative</td>
<td>08 to 10</td>
</tr>
<tr>
<td>Nigel Fleeman</td>
<td>ERG representative</td>
<td>08 to 10</td>
</tr>
<tr>
<td>Chris Chesters</td>
<td>NICE Observer</td>
<td>04 to 07</td>
</tr>
<tr>
<td>Katie Wyart</td>
<td>NICE Observer</td>
<td>04 to 07</td>
</tr>
<tr>
<td>Liz Adelanwa</td>
<td>NICE Observer</td>
<td>08 to 11</td>
</tr>
<tr>
<td>Edgar Masanga</td>
<td>NICE Observer</td>
<td>04 to 07</td>
</tr>
<tr>
<td>Hiral Shah</td>
<td>NICE Observer</td>
<td>all notes</td>
</tr>
</tbody>
</table>

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Sacubitril valsartan for treating heart failure with systolic dysfunction and Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.
2. The Chair welcomed Professor Andrew Renehan and Dr Ian Bernstein to their first meeting as a members of the Appraisal Committee

3. Apologies were received from Professor Eugene Milne, Dr Iain Miller and Professor Stephen O’Brien

Any other Business

4. None

Appraisal of Sacubitril valsartan for treating heart failure with systolic dysfunction

Part 1 – Open session

5. The Chair welcomed company representatives from Novartis to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

Professor Kathryn Abel, Dr Ian Bernstein, David Chandler, Gail Coster, Professor Peter Crome, Professor Rachel Elliott, Dr Nigel Langford, Dr Paul Miller, Professor Andrea Manca, Dr Patrick McKiernan, Dr Anna O’Neill, Professor Andrew Renehan, Dr Claire Rothery, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Dr Judith Wardle and Professor Robert Walton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Sacubitril valsartan for treating heart failure with systolic dysfunction.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Sacubitril valsartan for treating heart failure with systolic dysfunction.

8. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Sacubitril valsartan for treating heart failure with systolic dysfunction.

9. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of Sacubitril valsartan for treating heart failure with systolic dysfunction.

14. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy

Part 1 – Open session

15. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals Ltd to the meeting.

16. The Chair asked all Committee members to declare any relevant interests

16.1. Professor Kathryn Abel, Dr Ian Bernstein, David Chandler, Gail Coster, Professor Peter Crome, Professor Rachel Elliott, Dr Nigel Langford, Dr Paul Miller, Professor Andrea Manca, Dr Patrick McKiernan, Dr Anna O’Neill, Professor Andrew Renehan, Dr Claire Rothery, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Dr Judith Wardle and Professor Robert Walton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

17. The Chair asked all NICE Staff to declare any relevant interests.

17.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.
18. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

19. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

20. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

21. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

22. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

23. The Committee continued to discuss the clinical and cost effectiveness of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

24. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

25. Wednesday 09 March 2016 10:00 and to 17:00 at Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.